Literature DB >> 11336477

Decreasing of p27(Kip1)and cyclin E protein levels is associated with progression from superficial into invasive bladder cancer.

T Kamai1, K Takagi, H Asami, Y Ito, H Oshima, K I Yoshida.   

Abstract

The p27(Kip1)(p27) protein is a cyclin-dependent kinase inhibitor of the transition from G1 to S phase. It has been reported that decreased p27 protein level is a negative prognostic indicator in human tumours including bladder cancer. We studied the relationship between protein levels of p27, cyclin E and Ki-67 and clinicopathological features of 145 consecutive Japanese patients with transitional cell carcinoma of the bladder using immunohistochemical staining. Low protein levels of p27 were associated with low staining of cyclin E (P = 0.0302), high Ki-67 index (P = 0.0306), poorly differentiated grade (P = 0.0006), muscle invasion (P = 0.0019) and lymph node metastsis (P = 0.0002). Low staining of cyclin E and high Ki-67 index correlated with poorly differentiated grade, muscle invasion and lymph node metastsis. Cyclin E protein levels was inversely related with Ki-67 index (P = 0.0002). Kaplan-Meier plots of survival rate in patients with low versus high p27 staining showed that low protein levels of p27 were associated with a shortened disease-free and overall survival (P< 0.0001 and P< 0.0001, respectively). Similarly, low staining of cyclin E and high Ki-67 index correlated with a shortened disease-free and overall survival. On multivariate analysis using Cox proportional hazards model, low protein levels of p27 and high Ki-67 index were independent predictors of shortened disease-free (P< 0.0001, P = 0.0031, respectively), and low protein levels of p27, low staining of cyclin E and high Ki-67 index of overall survival (P = 0.0017, P = 0.0009, P = 0.0003, respectively). In superficial bladder tumours (Ta, T1; 86 patients), significant correlations were observed between low p27 staining and high Ki-67 index and early recurrence (P = 0.0048, P = 0.0178, respectively). Among the recurrenced superficial tumours (35 patients), the tumours which remained at a low stage showed high protein levels of p27 and cyclin E, and the tumours which progressed to invasive disease showed a gradual decrease in p27 and cyclin E protein levels over time. Our findings suggest that decreased protein levels of p27 and cyclin E play a role in the progression of bladder cancer and to evaluate these protein levels may be useful in management of the diseases. Copyright 2001 Cancer Research Campaign http://www.bjcancer.com.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11336477      PMCID: PMC2363875          DOI: 10.1054/bjoc.2000.1736

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  34 in total

1.  Cancer prognostics: past, present and p27.

Authors:  P S Steeg; J S Abrams
Journal:  Nat Med       Date:  1997-02       Impact factor: 53.440

2.  Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas.

Authors:  M Loda; B Cukor; S W Tam; P Lavin; M Fiorentino; G F Draetta; J M Jessup; M Pagano
Journal:  Nat Med       Date:  1997-02       Impact factor: 53.440

3.  Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients.

Authors:  P L Porter; K E Malone; P J Heagerty; G M Alexander; L A Gatti; E J Firpo; J R Daling; J M Roberts
Journal:  Nat Med       Date:  1997-02       Impact factor: 53.440

4.  Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer.

Authors:  C Catzavelos; N Bhattacharya; Y C Ung; J A Wilson; L Roncari; C Sandhu; P Shaw; H Yeger; I Morava-Protzner; L Kapusta; E Franssen; K I Pritchard; J M Slingerland
Journal:  Nat Med       Date:  1997-02       Impact factor: 53.440

5.  Significance of cyclin D1 overexpression in transitional cell carcinomas of the urinary bladder and its correlation with histopathologic features.

Authors:  C C Lee; S Yamamoto; K Morimura; H Wanibuchi; N Nishisaka; S Ikemoto; T Nakatani; S Wada; T Kishimoto; S Fukushima
Journal:  Cancer       Date:  1997-02-15       Impact factor: 6.860

6.  p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21.

Authors:  H Toyoshima; T Hunter
Journal:  Cell       Date:  1994-07-15       Impact factor: 41.582

Review 7.  Apparent failure of current intravesical chemotherapy prophylaxis to influence the long-term course of superficial transitional cell carcinoma of the bladder.

Authors:  D L Lamm; D R Riggs; C L Traynelis; U O Nseyo
Journal:  J Urol       Date:  1995-05       Impact factor: 7.450

8.  Factors influencing the recurrence rate of bladder cancer.

Authors:  S Loening; A Narayana; L Yoder; D Slymen; S Weinstein; G Penick; D Culp
Journal:  J Urol       Date:  1980-01       Impact factor: 7.450

9.  Deregulation of cyclin E in breast cancer.

Authors:  K Keyomarsi; D Conte; W Toyofuku; M P Fox
Journal:  Oncogene       Date:  1995-09-07       Impact factor: 9.867

Review 10.  Bacillus Calmette-Guérin in superficial bladder cancer: consensus and controversies.

Authors:  P D Vegt; F M Debruyne; A P van der Meijden
Journal:  Eur Urol       Date:  1995       Impact factor: 20.096

View more
  24 in total

Review 1.  Molecular markers of prognosis and novel therapeutic strategies for urothelial cell carcinomas.

Authors:  Christopher Y Thomas; Dan Theodorescu
Journal:  World J Urol       Date:  2006-11       Impact factor: 4.226

Review 2.  Molecular substratification of bladder cancer: moving towards individualized patient management.

Authors:  Anirban P Mitra
Journal:  Ther Adv Urol       Date:  2016-03-28

3.  Preprogramming therapeutic response of PI3K/mTOR dual inhibitor via the regulation of EHMT2 and p27 in pancreatic cancer.

Authors:  Yu-Feng Tian; Hui-Ching Wang; Chi-Wen Luo; Wen-Chun Hung; Yu-Han Lin; Tzu-Yi Chen; Chien-Feng Li; Chen-Yi Lin; Mei-Ren Pan
Journal:  Am J Cancer Res       Date:  2018-09-01       Impact factor: 6.166

4.  P27(Kip1) and Ki-67 expression analysis in transitional cell carcinoma of the bladder.

Authors:  Bartosz Dybowski; Jolanta Kupryjańczyk; Alina Rembiszewska; Roman Pykało; Andrzej Borkowski
Journal:  Urol Res       Date:  2003-09-27

5.  Expression of the cyclin-dependent kinase inhibitor p27 in transitional cell bladder cancers: is it a good predictor for tumor behavior?

Authors:  Latife Doganay; Semsi Altaner; Selcuk Bilgi; Esat Kaya; Galip Ekuklu; Kemal Kutlu
Journal:  Int Urol Nephrol       Date:  2003       Impact factor: 2.370

6.  Cystatin B as a tissue and urinary biomarker of bladder cancer recurrence and disease progression.

Authors:  Adam S Feldman; Jacqueline Banyard; Chin-Lee Wu; W Scott McDougal; Bruce R Zetter
Journal:  Clin Cancer Res       Date:  2009-02-01       Impact factor: 12.531

7.  Biomarkers in bladder cancer: present status and perspectives.

Authors:  Wun-Jae Kim; Soongang Park; Yong-June Kim
Journal:  Biomark Insights       Date:  2007-03-27

Review 8.  Prognostic value of cell-cycle regulation biomarkers in bladder cancer.

Authors:  Anirban P Mitra; Donna E Hansel; Richard J Cote
Journal:  Semin Oncol       Date:  2012-10       Impact factor: 4.929

9.  Cyclin D1 and cyclin E2 are differentially expressed in gastric cancer.

Authors:  Soni Kumari; Shyam Babu Prasad; Suresh Singh Yadav; Mohan Kumar; A Khanna; V K Dixit; Gopal Nath; Sunita Singh; Gopeshwar Narayan
Journal:  Med Oncol       Date:  2016-03-31       Impact factor: 3.064

10.  Targeted therapies in the management of metastatic bladder cancer.

Authors:  Matteo Fassan; Edouard J Trabulsi; Leonard G Gomella; Raffaele Baffa
Journal:  Biologics       Date:  2007-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.